Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 3 5 versus TRAVASOL 2 75 SULFITE FREE W ELECTROLYTES IN DEXTROSE 25 IN PLASTIC CONTAINER.
Head-to-head clinical analysis: AMINOSYN 3 5 versus TRAVASOL 2 75 SULFITE FREE W ELECTROLYTES IN DEXTROSE 25 IN PLASTIC CONTAINER.
AMINOSYN 3.5% vs TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 3.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, thereby promoting nitrogen balance and tissue repair.
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% is a parenteral nutrition solution providing calories (dextrose), amino acids (for protein synthesis), and electrolytes for maintenance of acid-base balance and cellular function. Dextrose is metabolized to glucose, which undergoes glycolysis and oxidative phosphorylation. Amino acids are used for protein synthesis and as an energy source. Electrolytes correct or prevent deficiencies.
Intravenous administration of 500 mL to 1000 mL per day as a 3.5% amino acid solution, typically infused at a rate of 1.25-2.5 mL/min (equivalent to 0.25-0.5 g amino acids/kg/day). Dose individualized based on nitrogen requirements and metabolic status.
Intravenous infusion only. Adult dose determined by nutritional requirements and metabolic tolerance. Typical dose: 500-2000 mL/day infused continuously or intermittently, with dextrose dosage not exceeding 0.5 g/kg/h. Final concentration of dextrose and amino acids must be monitored.
None Documented
None Documented
The plasma half-life of individual amino acids varies; for total amino acid mixture, the terminal elimination half-life is approximately 1-2 hours in patients with normal hepatic and renal function, reflecting rapid uptake into tissues and metabolism. This half-life is clinically relevant for continuous infusion scheduling.
Dextrose: rapid, minutes (insulin dependent); amino acids: 20-30 min for free pool turnover; electrolytes: distribution half-life 2-4 hours, elimination depends on renal function. Clinical: continuous infusion maintains steady state.
Amino acids are primarily eliminated via hepatic metabolism (deamination, transamination) and renal excretion. The renal excretion accounts for approximately 5-10% of the administered dose as unchanged amino acids; the majority is metabolized, and nitrogen is excreted as urea (80-90% of nitrogen) via urine, with minor fecal losses (<5%).
Primarily renal (glomerular filtration). Dextrose is completely metabolized; electrolytes (sodium, chloride, potassium, calcium, magnesium, acetate) are excreted via kidneys. Acetate is metabolized to bicarbonate. No significant biliary/fecal elimination.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution